Trials / Recruiting
RecruitingNCT06768671
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years at the Time of Study Inclusion With Active Moderate to Severe Hidradenitis Suppurativa
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- MoonLake Immunotherapeutics AG · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sonelokimab | Open label |
Timeline
- Start date
- 2024-12-30
- Primary completion
- 2026-03-27
- Completion
- 2026-03-27
- First posted
- 2025-01-10
- Last updated
- 2025-12-15
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06768671. Inclusion in this directory is not an endorsement.